OpenAI Acquires Orchestra Bio to Accelerate Rosalind Life Sciences Initiative
Sign in✓ Signed in
OpenAI announced the acquisition of Orchestra Bio, a biotech AI startup, integrating the team and its technology into Rosalind, the company's life sciences research platform. The deal, announced today, brings Orchestra's expertise in drug development coordination and AI agents into OpenAI's broader effort to compress timelines in pharmaceutical research.
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.
Unlocking the full article...